Homework Help is Here – Start Your Trial Now!
Business
Accounting
How should the capital market react to (a) the disclosure that a patent infringement suit involving Plavix had been filed against BMY and (b) the disclosure that the suit had been lost (won)

How should the capital market react to (a) the disclosure that a patent infringement suit involving Plavix had been filed against BMY and (b) the disclosure that the suit had been lost (won)

FINANCIAL ACCOUNTING
FINANCIAL ACCOUNTING
10th Edition
ISBN:9781259964947
Author:Libby
Publisher:Libby
Chapter1: Financial Statements And Business Decisions
Section: Chapter Questions
Problem 1Q
See similar textbooks
icon
Related questions
Question

How should the capital market react to (a) the disclosure that a patent infringement suit involving Plavix had been filed against BMY and (b) the disclosure that the suit had been lost (won)

Legal Proceedings: Patent Infringement. Bristol-Myers Squibb Company (BMY) engages in the discovery, development, license, manufacture, marketing, distribution, and sale of pharmaceutical and other health care products. Selected financial information for the company is as follows: Year 2 Year 1 Revenue. Net income $19.4 billion $20.9 billion 2.4 billion 3.1 billion Total assets 30.4 billion 20.2 billion 27.5 billion Total liabilities. 17.7 billion BMY's Year 2 annual report disclosed the following information in its footnote: Legal Proceedings and Contingencies Various lawsuits, claims, proceedings, and investiga- tions are pending against the Company and certain of its subsidiaries. In accordance with SFAS No. 5, Accounting for Contingencies, the Company records accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably esti- mated. These matters involve antitrust, securities, patent infringements, the Employee Retire- ment Income Security Act of 1974, as amended (ERISA), pricing, sales and marketing practices, environmental, health and safety matters, product liability and insurance coverage. The most significant of these matters are described on the next page. Plavix Litigation The Company's U.S. territory partnership under its alliance with Sanofi is a plaintiff in three pending patent infringement lawsuits instituted in the U.S. District Court for the Southem District of New York. Plaintiffs' infringement position is based on defendants filing of their Abbreviated New Drug Application (ANDA) with the FDA, seeking approval to sell generic clopido- grel bisulfate prior to the expiration of the composition of matter patent in Year 9. Plavix is currently the Company's largest product ranked by net sales. Net sales of Plavix were approximately $3.3 billion and $2.5 billion for the years ended December 31, Year 2 and Year 1, respectively. Loss of market exclusivity of Plavix and the subsequent development of generic competition would be material to the Company's sales of Plavix and results of operations and cash flows and could be material to its financial condition and liquidity.
Transcribed Image Text:Legal Proceedings: Patent Infringement. Bristol-Myers Squibb Company (BMY) engages in the discovery, development, license, manufacture, marketing, distribution, and sale of pharmaceutical and other health care products. Selected financial information for the company is as follows: Year 2 Year 1 Revenue. Net income $19.4 billion $20.9 billion 2.4 billion 3.1 billion Total assets 30.4 billion 20.2 billion 27.5 billion Total liabilities. 17.7 billion BMY's Year 2 annual report disclosed the following information in its footnote: Legal Proceedings and Contingencies Various lawsuits, claims, proceedings, and investiga- tions are pending against the Company and certain of its subsidiaries. In accordance with SFAS No. 5, Accounting for Contingencies, the Company records accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably esti- mated. These matters involve antitrust, securities, patent infringements, the Employee Retire- ment Income Security Act of 1974, as amended (ERISA), pricing, sales and marketing practices, environmental, health and safety matters, product liability and insurance coverage. The most significant of these matters are described on the next page. Plavix Litigation The Company's U.S. territory partnership under its alliance with Sanofi is a plaintiff in three pending patent infringement lawsuits instituted in the U.S. District Court for the Southem District of New York. Plaintiffs' infringement position is based on defendants filing of their Abbreviated New Drug Application (ANDA) with the FDA, seeking approval to sell generic clopido- grel bisulfate prior to the expiration of the composition of matter patent in Year 9. Plavix is currently the Company's largest product ranked by net sales. Net sales of Plavix were approximately $3.3 billion and $2.5 billion for the years ended December 31, Year 2 and Year 1, respectively. Loss of market exclusivity of Plavix and the subsequent development of generic competition would be material to the Company's sales of Plavix and results of operations and cash flows and could be material to its financial condition and liquidity.
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 2 steps

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer
Knowledge Booster
Accounting for Current liabilities, Provisions and Contingencies
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Recommended textbooks for you
FINANCIAL ACCOUNTING
FINANCIAL ACCOUNTING
Accounting
ISBN:
9781259964947
Author:
Libby
Publisher:
MCG
Accounting
Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,
Accounting Information Systems
Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,
Horngren's Cost Accounting: A Managerial Emphasis…
Horngren's Cost Accounting: A Managerial Emphasis…
Accounting
ISBN:
9780134475585
Author:
Srikant M. Datar, Madhav V. Rajan
Publisher:
PEARSON
Intermediate Accounting
Intermediate Accounting
Accounting
ISBN:
9781259722660
Author:
J. David Spiceland, Mark W. Nelson, Wayne M Thomas
Publisher:
McGraw-Hill Education
Financial and Managerial Accounting
Financial and Managerial Accounting
Accounting
ISBN:
9781259726705
Author:
John J Wild, Ken W. Shaw, Barbara Chiappetta Fundamental Accounting Principles
Publisher:
McGraw-Hill Education
SEE MORE TEXTBOOKS